Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly has amassed a market value nearing a trillion dollars based on the assumption that demand for its new weight-loss ...

Eli Lilly will release its third-quarter results this Wednesday. Investors are keen to see how the company has performed, ...

Conditions are getting a bit more challenging for the drugmaker.

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

Sales of Eli Lilly’s (LLY) blockbuster weight loss drug Zepbound are still booming, but just not at the level Wall Street was ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...